Veterinary Medicines

VANGUARD 7.

Authorised
  • Leptospira interrogans, serogroup Canicola, serovar Canicola, strain C51, Inactivated
  • Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain NADL 11403, Inactivated
  • Canine distemper virus, strain N-CDV, Live
  • Canine adenovirus 2, strain Manhattan, Live
  • Canine parainfluenza virus, strain NL-CPI-5, Live
  • Canine parvovirus, strain NL-35-D, Live
Download as PDF

Product identification

Medicine name:
VANGUARD 7.
Active substance:
  • Leptospira interrogans, serogroup Canicola, serovar Canicola, strain C51, Inactivated
  • Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain NADL 11403, Inactivated
  • Canine distemper virus, strain N-CDV, Live
  • Canine adenovirus 2, strain Manhattan, Live
  • Canine parainfluenza virus, strain NL-CPI-5, Live
  • Canine parvovirus, strain NL-35-D, Live
Target species:
  • Dog
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Leptospira interrogans, serogroup Canicola, serovar Canicola, strain C51, Inactivated
    740.00
    unit(s)
    /
    1.00
    millilitre(s)
  • Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain NADL 11403, Inactivated
    915.00
    unit(s)
    /
    1.00
    millilitre(s)
  • Canine distemper virus, strain N-CDV, Live
    1000.00
    50% cell culture infectious dose
    /
    1.00
    millilitre(s)
  • Canine adenovirus 2, strain Manhattan, Live
    1584.89
    50% cell culture infectious dose
    /
    1.00
    millilitre(s)
  • Canine parainfluenza virus, strain NL-CPI-5, Live
    1000000.00
    50% cell culture infectious dose
    /
    1.00
    millilitre(s)
  • Canine parvovirus, strain NL-35-D, Live
    10000000.00
    50% cell culture infectious dose
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Lyophilisate and solvent for solution for injection
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI07AI02
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Ireland
Available in:
  • Ireland
Package description:
  • The vaccine is filled in 1 dose vials glass type I (Ph.Eur.). Vials of the freeze-driedfraction are closed with a bromobutyl rubber stopper and a varnished aluminium cap.Vials of the liquid fraction are closed with a chlorobutyl rubber stopper and avarnished aluminium cap.Pack contains 100 vials of Vanguard DA2Pi freeze-dried fraction and 100 vials of 1 ml VanguardÔ CPV-L liquid fraction.
  • The vaccine is filled in 1 dose vials glass type I (Ph.Eur.). Vials of the freeze-driedfraction are closed with a bromobutyl rubber stopper and a varnished aluminium cap.Vials of the liquid fraction are closed with a chlorobutyl rubber stopper and avarnished aluminium cap.Pack contains 25 vials of Vanguard DA2Pi freeze-dried fraction and 25 vials of 1 ml VanguardÔ CPV-L liquid fraction.
  • The vaccine is filled in 1 dose vials glass type I (Ph.Eur.). Vials of the freeze-driedfraction are closed with a bromobutyl rubber stopper and a varnished aluminium cap.Vials of the liquid fraction are closed with a chlorobutyl rubber stopper and avarnished aluminium cap.Pack contains 10 vials of Vanguard DA2Pi freeze-dried fraction and 10 vials of 1 ml VanguardÔ CPV-L liquid fraction.
  • The vaccine is filled in 1 dose vials glass type I (Ph.Eur.). Vials of the freeze-driedfraction are closed with a bromobutyl rubber stopper and a varnished aluminium cap.Vials of the liquid fraction are closed with a chlorobutyl rubber stopper and avarnished aluminium cap.Pack contains 1 vial of Vanguard DA2Pi freeze-dried fraction and 1 vial of 1 ml VanguardÔ CPV-L liquid fraction.

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Zoetis Belgium S.A.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Zoetis Belgium
Responsible authority:
  • Health Products Regulatory Authority
Authorisation number:
  • VPA10387/082/001
Date of authorisation status change:

Documents

Summary of Product Characteristics

English (PDF)
Published on: 3/05/2024
Download